Clinical Trials Browser

Interventional × Tumor Lysis Syndrome × rasburicase × Clear all

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Phase 2 Completed

55 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Completed

82 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00360438 2012-08-01

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Phase 1/2 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3 Completed

280 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4 Completed

94 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

NCT00651911 2008-04-03

Fasturtec TLS Treatment / Prophylysis

Phase 4 Completed

45 enrolled

Tumor Lysis Syndrome

Clinical Trials

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Fasturtec TLS Treatment / Prophylysis